TY  - CONF
AU  - Jovanović, Marija
AU  - Sokić, Dragoslav
AU  - Grabnar, Iztok
AU  - Vovk, Tomaz
AU  - Prostran, Milica
AU  - Erić, Slavica
AU  - Kuzmanovski, Igor
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2453
PB  - Wiley-Blackwell, Hoboken
C3  - Pharmacotherapy
T1  - Prediction of topiramate serum levels according to variability factors using artificial neural networks.
VL  - 35
IS  - 5
SP  - e75
EP  - e76
DO  - 10.1002/phar.1606
ER  - 

@conference{
author = "Jovanović, Marija and Sokić, Dragoslav and Grabnar, Iztok and Vovk, Tomaz and Prostran, Milica and Erić, Slavica and Kuzmanovski, Igor and Vučićević, Katarina and Miljković, Branislava",
year = "2015",
publisher = "Wiley-Blackwell, Hoboken",
journal = "Pharmacotherapy",
title = "Prediction of topiramate serum levels according to variability factors using artificial neural networks.",
volume = "35",
number = "5",
pages = "e75-e76",
doi = "10.1002/phar.1606"
}

Jovanović, M., Sokić, D., Grabnar, I., Vovk, T., Prostran, M., Erić, S., Kuzmanovski, I., Vučićević, K.,& Miljković, B.. (2015). Prediction of topiramate serum levels according to variability factors using artificial neural networks.. in Pharmacotherapy
Wiley-Blackwell, Hoboken., 35(5), e75-e76.
https://doi.org/10.1002/phar.1606

Jovanović M, Sokić D, Grabnar I, Vovk T, Prostran M, Erić S, Kuzmanovski I, Vučićević K, Miljković B. Prediction of topiramate serum levels according to variability factors using artificial neural networks.. in Pharmacotherapy. 2015;35(5):e75-e76.
doi:10.1002/phar.1606 .

Jovanović, Marija, Sokić, Dragoslav, Grabnar, Iztok, Vovk, Tomaz, Prostran, Milica, Erić, Slavica, Kuzmanovski, Igor, Vučićević, Katarina, Miljković, Branislava, "Prediction of topiramate serum levels according to variability factors using artificial neural networks." in Pharmacotherapy, 35, no. 5 (2015):e75-e76,
https://doi.org/10.1002/phar.1606 . .

TY  - JOUR
AU  - Jovanović, Marija
AU  - Sokić, Dragoslav
AU  - Grabnar, Iztok
AU  - Vovk, Tomaz
AU  - Prostran, Milica
AU  - Erić, Slavica
AU  - Kuzmanovski, Igor
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2366
AB  - Purpose: The application of artificial neural networks in the pharmaceutical sciences is broad, ranging from drug discovery to clinical pharmacy. In this study, we explored the applicability of counter-propagation artificial neural networks (CPANNs), combined with genetic algorithm (GA) for prediction of topiramate (TPM) serum levels based on identified factors important for its prediction. Methods: The study was performed on 118 TPM measurements obtained from 78 adult epileptic patients. Patients were on stable TPM dosing regimen for at least 7 days; therefore, steady-state was assumed. TPM serum concentration was determined by high performance liquid chromatography with fluorescence detection. The influence of demographic, biochemical parameters and therapy characteristics of the patients on TPM levels were tested. Data analysis was performed by CPANNs. GA was used for optimal CPANN parameters, variable selection and adjustment of relative importance. Results: Data for training included 88 measured TPM concentrations, while remaining were used for validation. Among all factors tested, TPM dose, renal function (eGFR) and carbamazepine dose significantly influenced TPM level and their relative importance were 0.7500, 0.2813, 0.0625, respectively. Relative error and root mean squared relative error (%) and their corresponding 95% confidence intervals for training set were 2.14 [(-2.41) - 6.70] and 21.5 [18.5 - 24.1]; and for test set were 6.21 [(-21.2) - 8.77] and 39.9 [31.7 - 46.7], respectively. Conclusions: Statistical parameters showed acceptable predictive performance. Results indicate the feasibility of CPANNs combined with GA to predict TPM concentrations and to adjust relative importance of identified variability factors in population of adult epileptic patients.
PB  - Canadian Soc Pharmaceutical Sciences, Edmonton
T2  - Journal of Pharmacy and Pharmaceutical Sciences
T1  - Application of Counter-propagation Artificial Neural Networks in Prediction of Topiramate Concentration in Patients with Epilepsy
VL  - 18
IS  - 5
SP  - 856
EP  - 862
DO  - 10.18433/J33031
ER  - 

@article{
author = "Jovanović, Marija and Sokić, Dragoslav and Grabnar, Iztok and Vovk, Tomaz and Prostran, Milica and Erić, Slavica and Kuzmanovski, Igor and Vučićević, Katarina and Miljković, Branislava",
year = "2015",
abstract = "Purpose: The application of artificial neural networks in the pharmaceutical sciences is broad, ranging from drug discovery to clinical pharmacy. In this study, we explored the applicability of counter-propagation artificial neural networks (CPANNs), combined with genetic algorithm (GA) for prediction of topiramate (TPM) serum levels based on identified factors important for its prediction. Methods: The study was performed on 118 TPM measurements obtained from 78 adult epileptic patients. Patients were on stable TPM dosing regimen for at least 7 days; therefore, steady-state was assumed. TPM serum concentration was determined by high performance liquid chromatography with fluorescence detection. The influence of demographic, biochemical parameters and therapy characteristics of the patients on TPM levels were tested. Data analysis was performed by CPANNs. GA was used for optimal CPANN parameters, variable selection and adjustment of relative importance. Results: Data for training included 88 measured TPM concentrations, while remaining were used for validation. Among all factors tested, TPM dose, renal function (eGFR) and carbamazepine dose significantly influenced TPM level and their relative importance were 0.7500, 0.2813, 0.0625, respectively. Relative error and root mean squared relative error (%) and their corresponding 95% confidence intervals for training set were 2.14 [(-2.41) - 6.70] and 21.5 [18.5 - 24.1]; and for test set were 6.21 [(-21.2) - 8.77] and 39.9 [31.7 - 46.7], respectively. Conclusions: Statistical parameters showed acceptable predictive performance. Results indicate the feasibility of CPANNs combined with GA to predict TPM concentrations and to adjust relative importance of identified variability factors in population of adult epileptic patients.",
publisher = "Canadian Soc Pharmaceutical Sciences, Edmonton",
journal = "Journal of Pharmacy and Pharmaceutical Sciences",
title = "Application of Counter-propagation Artificial Neural Networks in Prediction of Topiramate Concentration in Patients with Epilepsy",
volume = "18",
number = "5",
pages = "856-862",
doi = "10.18433/J33031"
}

Jovanović, M., Sokić, D., Grabnar, I., Vovk, T., Prostran, M., Erić, S., Kuzmanovski, I., Vučićević, K.,& Miljković, B.. (2015). Application of Counter-propagation Artificial Neural Networks in Prediction of Topiramate Concentration in Patients with Epilepsy. in Journal of Pharmacy and Pharmaceutical Sciences
Canadian Soc Pharmaceutical Sciences, Edmonton., 18(5), 856-862.
https://doi.org/10.18433/J33031

Jovanović M, Sokić D, Grabnar I, Vovk T, Prostran M, Erić S, Kuzmanovski I, Vučićević K, Miljković B. Application of Counter-propagation Artificial Neural Networks in Prediction of Topiramate Concentration in Patients with Epilepsy. in Journal of Pharmacy and Pharmaceutical Sciences. 2015;18(5):856-862.
doi:10.18433/J33031 .

Jovanović, Marija, Sokić, Dragoslav, Grabnar, Iztok, Vovk, Tomaz, Prostran, Milica, Erić, Slavica, Kuzmanovski, Igor, Vučićević, Katarina, Miljković, Branislava, "Application of Counter-propagation Artificial Neural Networks in Prediction of Topiramate Concentration in Patients with Epilepsy" in Journal of Pharmacy and Pharmaceutical Sciences, 18, no. 5 (2015):856-862,
https://doi.org/10.18433/J33031 . .

TY  - CONF
AU  - Jovanović, Marija
AU  - Sokić, Dragoslav
AU  - Grabnar, Iztok
AU  - Prostran, Milica
AU  - Obrenović, Radmila
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2198
PB  - Wiley-Blackwell, Hoboken
C3  - Pharmacotherapy
T1  - Influence of topiramate therapy duration on serum bicarbonate levels in adults
VL  - 34
IS  - 6
SP  - e110
EP  - e110
DO  - 10.1002/phar.1449
ER  - 

@conference{
author = "Jovanović, Marija and Sokić, Dragoslav and Grabnar, Iztok and Prostran, Milica and Obrenović, Radmila and Vučićević, Katarina and Miljković, Branislava",
year = "2014",
publisher = "Wiley-Blackwell, Hoboken",
journal = "Pharmacotherapy",
title = "Influence of topiramate therapy duration on serum bicarbonate levels in adults",
volume = "34",
number = "6",
pages = "e110-e110",
doi = "10.1002/phar.1449"
}

Jovanović, M., Sokić, D., Grabnar, I., Prostran, M., Obrenović, R., Vučićević, K.,& Miljković, B.. (2014). Influence of topiramate therapy duration on serum bicarbonate levels in adults. in Pharmacotherapy
Wiley-Blackwell, Hoboken., 34(6), e110-e110.
https://doi.org/10.1002/phar.1449

Jovanović M, Sokić D, Grabnar I, Prostran M, Obrenović R, Vučićević K, Miljković B. Influence of topiramate therapy duration on serum bicarbonate levels in adults. in Pharmacotherapy. 2014;34(6):e110-e110.
doi:10.1002/phar.1449 .

Jovanović, Marija, Sokić, Dragoslav, Grabnar, Iztok, Prostran, Milica, Obrenović, Radmila, Vučićević, Katarina, Miljković, Branislava, "Influence of topiramate therapy duration on serum bicarbonate levels in adults" in Pharmacotherapy, 34, no. 6 (2014):e110-e110,
https://doi.org/10.1002/phar.1449 . .

TY  - JOUR
AU  - Jovanović, Marija
AU  - Sokić, Dragoslav
AU  - Grabnar, Iztok
AU  - Prostran, Milica
AU  - Obrenović, Radmila
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2091
AB  - Background: Topiramate (TPM) is a sulfamate-substituted monosaccharide that is structurally different from other antiepileptic drugs. TPM inhibits carbonic anhydrase activity, which is associated with loss of bicarbonate from the kidney and consequently metabolic acidosis or electrolyte imbalance. Objective: The objectives of the study were to investigate the influence of TPM therapy on bicarbonate and potassium levels in adult epileptic patients. Methods: Data were collected from 59 adult patients on monotherapy or co-therapy of TPM and other antiepileptic drugs. Serum bicarbonate and potassium levels were available from all patients. Steady-state TPM trough concentrations were determined in blood samples by high-performance liquid chromatography. Data analysis was performed by SPSS software (version 17, Chicago, IL). Results: Patients were divided into group A (duration of therapy shorter than or equal to 5 years) and group B (duration of therapy longer than 5 years). Significant difference (P  lt  0.05) in serum bicarbonate levels was observed between these 2 groups. Bicarbonate levels were linearly related to the TPM therapy duration. No correlation was found between the TPM dose or patient age and bicarbonate or potassium levels, as well as between therapy duration and potassium level. Linear regression analysis showed no significant association among 54 available TPM trough concentrations and bicarbonate or potassium levels. Conclusions: Results highlight the frequent occurrence of lower bicarbonate level associated with prolonged TPM therapy. Monitoring bicarbonate levels in patients on long-term TPM therapy might be useful.
PB  - Sage Publications Inc, Thousand Oaks
T2  - Annals of Pharmacotherapy
T1  - Effect of Long-term Topiramate Therapy on Serum Bicarbonate and Potassium Levels in Adult Epileptic Patients
VL  - 48
IS  - 8
SP  - 992
EP  - 997
DO  - 10.1177/1060028014534397
ER  - 

@article{
author = "Jovanović, Marija and Sokić, Dragoslav and Grabnar, Iztok and Prostran, Milica and Obrenović, Radmila and Vučićević, Katarina and Miljković, Branislava",
year = "2014",
abstract = "Background: Topiramate (TPM) is a sulfamate-substituted monosaccharide that is structurally different from other antiepileptic drugs. TPM inhibits carbonic anhydrase activity, which is associated with loss of bicarbonate from the kidney and consequently metabolic acidosis or electrolyte imbalance. Objective: The objectives of the study were to investigate the influence of TPM therapy on bicarbonate and potassium levels in adult epileptic patients. Methods: Data were collected from 59 adult patients on monotherapy or co-therapy of TPM and other antiepileptic drugs. Serum bicarbonate and potassium levels were available from all patients. Steady-state TPM trough concentrations were determined in blood samples by high-performance liquid chromatography. Data analysis was performed by SPSS software (version 17, Chicago, IL). Results: Patients were divided into group A (duration of therapy shorter than or equal to 5 years) and group B (duration of therapy longer than 5 years). Significant difference (P  lt  0.05) in serum bicarbonate levels was observed between these 2 groups. Bicarbonate levels were linearly related to the TPM therapy duration. No correlation was found between the TPM dose or patient age and bicarbonate or potassium levels, as well as between therapy duration and potassium level. Linear regression analysis showed no significant association among 54 available TPM trough concentrations and bicarbonate or potassium levels. Conclusions: Results highlight the frequent occurrence of lower bicarbonate level associated with prolonged TPM therapy. Monitoring bicarbonate levels in patients on long-term TPM therapy might be useful.",
publisher = "Sage Publications Inc, Thousand Oaks",
journal = "Annals of Pharmacotherapy",
title = "Effect of Long-term Topiramate Therapy on Serum Bicarbonate and Potassium Levels in Adult Epileptic Patients",
volume = "48",
number = "8",
pages = "992-997",
doi = "10.1177/1060028014534397"
}

Jovanović, M., Sokić, D., Grabnar, I., Prostran, M., Obrenović, R., Vučićević, K.,& Miljković, B.. (2014). Effect of Long-term Topiramate Therapy on Serum Bicarbonate and Potassium Levels in Adult Epileptic Patients. in Annals of Pharmacotherapy
Sage Publications Inc, Thousand Oaks., 48(8), 992-997.
https://doi.org/10.1177/1060028014534397

Jovanović M, Sokić D, Grabnar I, Prostran M, Obrenović R, Vučićević K, Miljković B. Effect of Long-term Topiramate Therapy on Serum Bicarbonate and Potassium Levels in Adult Epileptic Patients. in Annals of Pharmacotherapy. 2014;48(8):992-997.
doi:10.1177/1060028014534397 .

Jovanović, Marija, Sokić, Dragoslav, Grabnar, Iztok, Prostran, Milica, Obrenović, Radmila, Vučićević, Katarina, Miljković, Branislava, "Effect of Long-term Topiramate Therapy on Serum Bicarbonate and Potassium Levels in Adult Epileptic Patients" in Annals of Pharmacotherapy, 48, no. 8 (2014):992-997,
https://doi.org/10.1177/1060028014534397 . .

TY  - JOUR
AU  - Jovanović, Marija
AU  - Sokić, Dragoslav
AU  - Grabnar, Iztok
AU  - Vovk, Tomaz
AU  - Prostran, Milica
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
PY  - 2013
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1844
AB  - The objective of the study was to develop population pharmacokinetic model of topiramate (TPM) using nonlinear mixed effects modelling approach. Data were collected from 78 adult epileptic patients on mono- or co-therapy of TPM and other antiepileptic drugs, such as carbamazepine (CBZ), valproic acid, lamotrigine, levetiracetam, phenobarbital and pregabalin. Steady-state TPM concentrations were determined in blood samples by high performance liquid chromatography with fluorescence detection. A one-compartment model with first order absorption and elimination was used to fit the concentration-time TPM data. Volume of distribution of TPM was estimated at 0.575 l/kg. The influence of demographic, biochemical parameters and therapy characteristics of the patients on oral clearance (CL/F) was evaluated. Daily carbamazepine dose (DCBZ) and renal function estimated by Modification of diet in renal disease (MDRD) formula significantly (p  lt  0.001) influenced CL/F and were included in the final model: CL/F . (l/h) = 1.53(1/h) . [1 + 0.476 . DCBZ(mg/day)/1000(mg/day)] . EXP[0.00476 . [MDRD(ml/min) -95.72(ml/ mm)]]. Increase of CL/F with DCBZ and MDRD was best described by linear and exponential models. Mean TPM CL/F during CBZ co-therapy was 2.46 l/h, which is higher for 60.8% than in patients not co-treated with CBZ. Evaluation by bootstrapping showed that the final model was stable. The predictive performance was evaluated by adequate plots and indicated satisfactory precision. This model allows individualisation of TPM dosing in routine patient care, especially useful for patients on different CBZ dosing regimen.
PB  - Elsevier Science BV, Amsterdam
T2  - European Journal of Pharmaceutical Sciences
T1  - Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling
VL  - 50
IS  - 3-4
SP  - 282
EP  - 289
DO  - 10.1016/j.ejps.2013.07.008
ER  - 

@article{
author = "Jovanović, Marija and Sokić, Dragoslav and Grabnar, Iztok and Vovk, Tomaz and Prostran, Milica and Vučićević, Katarina and Miljković, Branislava",
year = "2013",
abstract = "The objective of the study was to develop population pharmacokinetic model of topiramate (TPM) using nonlinear mixed effects modelling approach. Data were collected from 78 adult epileptic patients on mono- or co-therapy of TPM and other antiepileptic drugs, such as carbamazepine (CBZ), valproic acid, lamotrigine, levetiracetam, phenobarbital and pregabalin. Steady-state TPM concentrations were determined in blood samples by high performance liquid chromatography with fluorescence detection. A one-compartment model with first order absorption and elimination was used to fit the concentration-time TPM data. Volume of distribution of TPM was estimated at 0.575 l/kg. The influence of demographic, biochemical parameters and therapy characteristics of the patients on oral clearance (CL/F) was evaluated. Daily carbamazepine dose (DCBZ) and renal function estimated by Modification of diet in renal disease (MDRD) formula significantly (p  lt  0.001) influenced CL/F and were included in the final model: CL/F . (l/h) = 1.53(1/h) . [1 + 0.476 . DCBZ(mg/day)/1000(mg/day)] . EXP[0.00476 . [MDRD(ml/min) -95.72(ml/ mm)]]. Increase of CL/F with DCBZ and MDRD was best described by linear and exponential models. Mean TPM CL/F during CBZ co-therapy was 2.46 l/h, which is higher for 60.8% than in patients not co-treated with CBZ. Evaluation by bootstrapping showed that the final model was stable. The predictive performance was evaluated by adequate plots and indicated satisfactory precision. This model allows individualisation of TPM dosing in routine patient care, especially useful for patients on different CBZ dosing regimen.",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Journal of Pharmaceutical Sciences",
title = "Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling",
volume = "50",
number = "3-4",
pages = "282-289",
doi = "10.1016/j.ejps.2013.07.008"
}

Jovanović, M., Sokić, D., Grabnar, I., Vovk, T., Prostran, M., Vučićević, K.,& Miljković, B.. (2013). Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling. in European Journal of Pharmaceutical Sciences
Elsevier Science BV, Amsterdam., 50(3-4), 282-289.
https://doi.org/10.1016/j.ejps.2013.07.008

Jovanović M, Sokić D, Grabnar I, Vovk T, Prostran M, Vučićević K, Miljković B. Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling. in European Journal of Pharmaceutical Sciences. 2013;50(3-4):282-289.
doi:10.1016/j.ejps.2013.07.008 .

Jovanović, Marija, Sokić, Dragoslav, Grabnar, Iztok, Vovk, Tomaz, Prostran, Milica, Vučićević, Katarina, Miljković, Branislava, "Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling" in European Journal of Pharmaceutical Sciences, 50, no. 3-4 (2013):282-289,
https://doi.org/10.1016/j.ejps.2013.07.008 . .